<DOC>
	<DOCNO>NCT02961374</DOCNO>
	<brief_summary>This phase II trial study side effect erlotinib hydrochloride well work reduce duodenal polyp burden patient familial adenomatous polyposis risk develop colon cancer . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Erlotinib Hydrochloride Reducing Duodenal Polyp Burden Patients With Familial Adenomatous Polyposis Risk Developing Colon Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess mean percent change duodenal polyp burden ( sum diameter polyps ) baseline 6 month post-intervention familial adenomatous polyposis ( FAP ) subject receive weekly erlotinib hydrochloride ( erlotinib ) . II . To assess grade 2/3 adverse event rate population compare historical data . SECONDARY OBJECTIVES : I . To evaluate adverse event least possibly attributed weekly erlotinib . II . To assess absolute percent change duodenal polyp number baseline 6 month . III . To assess absolute percent change low gastrointestinal polyp burden number subset participant ileal pouch anal anastomosis ( IPAA ) ileo-rectal anastomosis rectal stump . IV . To assess absolute percent change desmoid tumor size participant baseline follow compute tomography ( CT ) perform part standard care . V. Gene expression profile duodenal adenoma uninvolved tissue compare baseline endpoint sample use negative binomial statistic ( DESeq2 ) . VI . Identify differentially express gene duodenal polyp uninvolved tissue endpoint compare baseline . VII . Evaluate effect weekly erlotinib EGFR Wnt target gene expression duodenal adenoma . VIII . Evaluate effect weekly erlotinib immune response signal duodenal adenoma uninvolved tissue . OUTLINE : Patients receive erlotinib hydrochloride orally ( PO ) weekly . Treatment continue 6 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>PREREGISTRATION INCLUSION Diagnosis familial adenomatous polyposis ( FAP ) attenuate familial adenomatous polyposis ( AFAP ) , define least one following : Genetic diagnosis confirm APC mutation ( Clinical Laboratory Improvement Act [ CLIA ] certify lab research test ) Obligate carrier Clinical diagnosis classic FAP &gt; = 100 colorectal adenoma status post colectomy family history FAP Spigelman 23 Uncontrolled intercurrent illness recent surgical procedure opinion investigative team would limit compliance study requirement , include , limited : Ongoing active infection Symptomatic congestive heart failure Myocardial infarction = &lt; 6 month prior intervention Severely impaired lung function Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study intervention Diagnosed liver disease , cirrhosis , chronic active hepatitis , chronic persistent hepatitis Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation Ability understand willingness sign write informed consent document Willingness discontinue take nonsteroidal antiinflammatory drug ( NSAIDS ) 30 day prior initiation intervention ; exception : use = &lt; 81 mg daily = &lt; 650 mg weekly aspirin allow Willingness discontinue smoke duration study intervention REGISTRATION INCLUSION Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Leukocytes ( white blood cell [ WBC ] ) &gt; = 3,000/uL ( &gt; = 2,500/uL AfricanAmerican participant ) Platelet count &gt; = 100 x 10^9/L Hemoglobin &gt; 11.5 g/dL Total bilirubin = &lt; 1.5 x institutional upper limit normal ( ULN ) Alkaline phosphatase = &lt; 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) = &lt; 2 x institutional upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) = &lt; 2 x institutional upper limit normal ( ULN ) Creatinine within institutional limit normal Urinary protein urinary cast within institutional limit normal Not pregnant breast feeding ; woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform study physician immediately ; breastfeed discontinue mother treated erlotinib Willingness use adequate contraception avoid pregnancy impregnation 2 week discontinue study agent Willingness provide mandatory biospecimens specify protocol PREREGISTRATION EXCLUSION Any prior treatment erlotinib agent whose primary mechanism action know inhibit EGFR History allergic reaction attribute compound similar chemical biologic composition erlotinib Use potent CYP3A4 inhibitor , ketoconazole , atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin , voriconazole , grapefruit grapefruit juice Use CYP3A4 inducer rifampicin , rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital , St. John 's wort Use investigational agent = &lt; 12 week prior preregistration History invasive malignancy = &lt; 3 year prior preregistration ; exception : adequately treat carcinoma cervix , carcinoma situ , basal squamous cell carcinoma skin Use anticoagulation medication , include limited coumadin , warfarin , plavix REGISTRATION EXCLUSION Histologicallyconfirmed high grade dysplasia ( HGD ) , cancer , polyp burden quantifiable Regular ( &gt; = 2 time per week ) use drug alter pH gastrointestinal tract ( GI ) tract , proton pump inhibitor ( PPI ) antacid ; exception : individual use prescription PPIs approval primary health care provider discontinue duration clinical trial participation may enrol ; alternate drug control gastroesophageal reflux disease ( GERD ) /peptic ulcer disease ( PUD ) symptom suggest Gastrointestinal bleeding ; note presence symptom ( dyspnea , fatigue , angina , weakness , malaise , melena , hematochezia , hematemesis , anemia , abdominal pain ) require clinical assessment rule gastrointestinal bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>